Guardant360 CDx
Guardant Health, Inc. · Decision date Sep 4, 2026
What did the FDA approve?
FDA records P200010/S024 as a supplement to PMA P200010, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Sep 4, 2026.
FDA approval order statement
Approval for expanding the indications for use to include a companion diagnostic claim for the detection of ESR1 mutations in patients with breast cancer who may benefit from treatment with ETCAMAH (camizestrant).
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Pathology
- Decision date
- Sep 4, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P200010/S024
- Regulatory pathway
- PMA supplement
- Applicant
- Guardant Health, Inc.
- Product code
- PQP
- Decision code
- APPR
- Decision date
- Sep 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Guardant Health, Inc.
- Product code
- PQP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P200010. Subsequent supplements may change the device or its indications.
FDA decision timeline
P200010 · Original PMA
Guardant360 CDx
P200010/S024 received
Application receipt date recorded by FDA.
P200010/S024 · FDA decision
Normal 180 Day Track
P200010/S029 · Related supplement
Guardant360 CDx
Timeline entries are records held by MedtechLedger for P200010. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200010
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Guardant360 CDxP200010 | Guardant Health, Inc. | PMA approval | Aug 7, 2020 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040/S008 | Life Technologies Corporation | PMA supplement | Nov 4, 2026 | FDA |
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
MI Cancer SeekP240010/S007 | Caris Life Sciences | PMA supplement | Oct 16, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
FoundationOne CDxP170019/S069 | Foundation Medicine, Inc. | PMA supplement | Sep 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Guardant Health, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 505 Penobscot Dr., Redwood City, CA, 94063
Sources and methodology
- Original FDA record: P200010/S024
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




